Abstract：OBJECTIVE: To study serum levels and clinical significance of insulin-like growth factor-1 (IGF-1) and growth factor binding protein 3 (IGFBP-3) in children with acute lymphocytic leukemia (ALL). METHODS: Serum samples were obtained from 36 children with ALL before treatment and 6 months after complete remission. Thirty children with surgical diseases severed as the control group. Serum IGF-1 levels were measured using radioimmunoassay (RIA). Serum IGFBP-3 levels were measured using immunoradioassays (IRMA). RESULTS: Serum levels of IGF-1 and IGFBP-3 in the ALL group were 19±4 ng/mL and 1216±132 ng/mL, respectively before treatment, which were lower than those in the control group (32±3 ng/mL and 2104±191 ng/mL respectively) (P<0.01). Serum levels of IGF-1 and IGFBP-3 in the ALL group increased to 30±3 ng/mL and 1941±164 ng/mL respectively 6 months after complete remission, which were significantly higher than those before treatment (P<0.01) and were similar to the levels of the control group. CONCLUSIONS: Serum levels of IGF-1 and IGFBP-3 are reduced in children with ALL, but increase significantly after complete remission, suggesting that IGF-1 and IGFBP-3 might serve as useful markers for the diagnosis and evaluation of therapeutic effects of childhood ALL.
ZHAO Dong-Ju,ZHANG Wen-Lin,SHI Tai-Xin. Serum levels of insulin-like growth factor-1 and growth factor binding protein-3 in children with acute lymphocytic leukemia[J]. CJCP, 2011, 13(2): 101-103.
［1］Zhao MD, Hu XM, Sun DJ, Zhang Q, Zhang YH, Meng W. Expression of some tumor associated factors in human carcinogenesis and development of gastric carcinoma［J］. World J Gastroenterol, 2005, 11(21): 3217-3221.
［2］Zumkeller W. The insulin-like growth factor system in hematopoietic cells［J］. Leuk Lymphoma, 2002, 43(3): 487-491.
［5］Stromberg T, Ekman S, Girnita L, Dimberg LY, Larsson O, Axelson M, et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2 /M-phase accumulation and apoptosis in multiple myeloma cells［J］.Blood, 2006, 107(2): 669-678.
［6］Ahlén J, Wejde J, Brosj-O, von Rosen A, Weng WH, Girnita L, et al.Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma［J］. Clin Cancer Res, 2005,11(1): 206-216.
［7］Serrano ML, Romero A, Cendales R,Sánchez-Gómez M, Bravo MM. Serum levels of insulin-like growth factor-I and -II and insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer［J］. Biomedica, 2006, 26(2): 258-268.
［8］Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Risch HA, Puopolo M, et al. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer［J］. Clin Cancer Res, 2006, 12(4):1208-1214.
［9］Sasaki J, Konishi F, Kawamura YJ, Kai T, Takata O, Tsukamoto T. Clinicopathological characteristics of colorectal cancers with loss of imprinting of insulinlike growth factor 2［J］. Int J Cancer, 2006, 119(1):80-83.
［10］Keehn CA, Saeed S, Bickle K, Khalil FK, Morgan MB. Expression of insulinlike growth factor-I receptor in primary cutaneous carcinomas［J］.J Cutan Pathol, 2004, 31(5):368-372.
［11］Argüelles B, Barrios V, Pozo J, Munoz MT, Argente J. Modifications of growth velocity and the insulin-like growth factor system in children with acute lyphoblastic leukemia: a longitudinal study［J］. J Clin Endocrinol Metab, 2000, 85(11):4087-4092.
